ECOG-ACRIN Cancer Research Group

Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer

Phase 2/3Not yet recruiting2027432 people1 Oct 2026clinicaltrials.gov

NCT07765433

Phase 2/3Not yet recruiting2027336 people14 Aug 2026clinicaltrials.gov

NCT07040280

Phase 2Recruiting2026120 people27 Jun 2025clinicaltrials.gov

NCT06205485

CollaboratorPhase 3Recruiting2024250 people16 Jan 2024clinicaltrials.gov

NCT05721755

Phase 3Active, not recruiting2023290 people10 Feb 2023clinicaltrials.gov

NCT04566328

Phase 3Recruiting20211,450 people28 Sept 2020clinicaltrials.gov

NCT04559139

Phase 2/3Active, not recruiting2021186 people22 Sept 2020clinicaltrials.gov

NCT04423211

Phase 3Recruiting2020804 people9 Jun 2020clinicaltrials.gov

NCT04266249

Phase 2Active, not recruiting20202,175 people12 Feb 2020clinicaltrials.gov

NCT04248452

Phase 3Active, not recruiting2020314 people30 Jan 2020clinicaltrials.gov

NCT03937635

Phase 3Recruiting2019288 people6 May 2019clinicaltrials.gov

NCT02734537

Phase 2Recruiting2016189 people12 Apr 2016clinicaltrials.gov

NCT02607423

Phase 2Withdrawn20150 people18 Nov 2015clinicaltrials.gov

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Phase 2Active, not recruiting201567 people3 Nov 2015clinicaltrials.gov

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

Phase 3Active, not recruiting2015415 people15 May 2015clinicaltrials.gov

NCT02412670

Phase 2Completed201536 people9 Apr 2015clinicaltrials.gov

NCT02305654

CollaboratorPhase 3Active, not recruiting2017200 people2 Dec 2014clinicaltrials.gov

NCT02085408

Phase 3Completed2011727 people12 Mar 2014clinicaltrials.gov

NCT02051868

CollaboratorPhase 2Status unknown201380 people31 Jan 2014clinicaltrials.gov

NCT02031536

Phase 2Terminated20142 people9 Jan 2014clinicaltrials.gov

Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study

Blood5 Oct 2026